NEI Fall Congress 2026: Program & Speakers

Adelaide S. Robb, MD

Approaches to managing irritability and emotional dysregulation in children and adolescents with autism spectrum disorder.

Jeffrey R. Strawn, MD, FAACAP

Weighs when to start, continue, or stop dopamine receptor blocking agents in pediatric patients, including safety and monitoring considerations.

Katherine K. Dahlsgaard, PhD, ABPP

Clinical strategies for evaluating and treating picky, restrictive, and disordered eating patterns in youth.

Jeffrey R. Strawn, MD, FAACAP · Katherine K. Dahlsgaard, PhD, ABPP

Recognition, assessment, and evidence-based pharmacologic and psychotherapeutic management of anxiety disorders in children and adolescents.

Timothy E. Wilens, MD

Managing ADHD complicated by executive dysfunction and psychiatric comorbidity, with practical treatment-optimization tactics.

Thomas L. Schwartz, MD

Reviews the neurobiology of sleep-wake circuits and sleep architecture, and offers a practical framework for diagnosing sleep disorders.

Covers orexin system physiology and the growing therapeutic role of orexin receptor antagonists and agonists across insomnia, hypersomnia, and mood disorders.

Thomas L. Schwartz, MD

Case-based walkthrough of real-world treatment decisions for common sleep disorders.

Andrew J. Cutler, MD · Kristian Dambrino, DNP, PMHNP-BC

When and how to deploy glutamatergic agents in major depressive disorder to improve functional recovery.

Stephen M. Stahl, MD, PhD, DSc (Hon.)

Treatment strategies for depression that has not responded to standard approaches.

Roger S. McIntyre, MD, FRCPC · Thomas L. Schwartz, MD

Applies shared decision-making to selecting and sequencing serotonin-dopamine activity partial agonists among MDD treatment options. Title reproduced exactly as published on the agenda.

Stephen M. Stahl, MD, PhD, DSc (Hon.)

Examines impaired illness awareness in schizophrenia spectrum disorders and its impact on engagement and treatment adherence.

Christoph U. Correll, MD

Makes the case for earlier use of long-acting injectable antipsychotics in serious mental illness, with shared decision-making strategies.

Stephen M. Stahl, MD, PhD, DSc (Hon.)

Reviews the mechanism and clinical positioning of muscarinic agonists across neuropsychiatric conditions.

Jeffrey R. Strawn, MD, FAACAP

Sharpens the diagnosis of generalized anxiety disorder and surveys its neurobiology and emerging treatment directions.

Jonathan M. Meyer, MD

Addresses recognition and treatment of depressive and mixed presentations across the bipolar spectrum.

Hara E. Oyedeji, DNP, PMHNP-BC · MSEd

Explores the functional and psychosocial burden of tardive dyskinesia and how to screen, assess, and monitor for it.

Leslie Citrome, MD, MPH · Hara E. Oyedeji, DNP, PMHNP-BC, MSEd

Live demonstration of how to administer the Abnormal Involuntary Movement Scale in practice.

Leslie Citrome, MD, MPH

Reviews the neurobiological rationale and clinical evidence behind current tardive dyskinesia treatments.

Jeffrey R. Strawn, MD, FAACAP · Stephen M. Stahl, MD, PhD, DSc (Hon.)

Practical guidance on when and how to taper or discontinue psychiatric medications safely.

Jennifer Payne, MD

Examines hormonally influenced depression across reproductive stages from puberty through perimenopause.

Jeffrey R. Strawn, MD, FAACAP · Andrew J. Cutler, MD

Links residual ADHD symptoms to underlying circuitry and offers strategies to optimize treatment response.

David W. Goodman, MD

Leslie Citrome, MD, MPH

Practical management of agitation in Alzheimer's disease alongside strategies to support caregivers.

Christine Moutier, MD

David W. Goodman, MD · Andrew J. Cutler, MD

Draws lessons from the Done.com telehealth prosecution for safe, ethical controlled-substance prescribing via telepsychiatry.

Roger S. McIntyre, MD, FRCPC

Jonathan M. Meyer, MD

Reviews older psychotropics with limited modern utility and current best practices for clozapine and lithium.

Andrew J. Cutler, MD · Roger S. McIntyre, MD, FRCPC

Explores reframing mental illness by highlighting creativity and societal contribution of people with psychiatric conditions.